biOasis Adds MarketSmart Communications Inc. to Investor Relations Team

Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) is pleased to announce it has entered into a consulting agreement (“Agreement”) for MarketSmart Communications Inc (“MarketSmart”) to provide investor relations services to the Company.

MarketSmart was established in 2002 and President, Maria Da Silva has worked with many TSX Venture Exchange companies to assist in helping companies with their corporate profile within the investment community.

“It is important that we are able to communicate to as wide an audience as possible about biOasis’s corporate achievements as we enter into an exciting phase for our company,” said Rob Hutchison, CEO of biOasis.

The Agreement is for a one year term. MarketSmart will receive fees for service of $5,000 per month and 150,000 incentive stock options with a one year term. Each option is exercisable into a common share of the Company at $0.48. The options are subject to vesting over 12 months as follows: 37,500 vest on July 15, 2011 and 37,500 vest each quarter thereafter. The options follow the guidelines as set out in the Company’s stock option plan and as set by TSX Venture Policy. Both the consulting agreement and the options grant are subject to the approval of the TSX Venture Exchange.


biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing CognitestTM, a blood test for the diagnosis of Alzheimer’s disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.


Since 2002 MarketSmart had been connecting sophisticated investors with promising companies by providing shareholder and investor communications services, public and media relations; e-mail marketing campaigns and increased web exposure. Contact Maria Da Silva 1-877-261-4466 or visit

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician’s Aid to Diagnose Alzheimer’s, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Robin Hutchison

Director and CEO

1-778-383-3280 Extension 101

[email protected]

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”


biOasis Technologies Inc.
Robin Hutchison, Director and CEO
1-778-383-3280 Extension 101
[email protected]